HarrisonDE, StrongR, SharpZD, et al.Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 2009; 460:392–395.
2.
MorrisBJ. Seven sirtuins for seven deadly diseases of aging. Free Radic Biol Med, 2013; 56:133–171.
3.
KenyonC. The first long-lived mutants: Discovery of the insulin/IGF-1 pathway for ageing. Philos Trans R Soc Lond B Biol Sci, 2011; 366:9–16.
4.
HubbardBP, SinclairDA. Small molecule SIRT1 activators for the treatment of aging and age-related diseases. Trends Pharmacol Sci, 2014; 35:146–154.
5.
BaurJA, PearsonKJ, PriceNL, et al.Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006; 444:337–342.
6.
MilneJC, LambertPD, SchenkS, et al.Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 2007; 450:712–716.
7.
BaurJA, SinclairDA. Therapeutic potential of resveratrol: The in vivo evidence. Nat Rev Drug Discov, 2006; 5:493–506.
8.
HowitzKT, BittermanKJ, CohenHY, et al.Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003; 425:191–196.
9.
LagougeM, ArgmannC, Gerhart-HinesZ, et al.Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006; 127:1109–1122.
10.
KimD, NguyenMD, DobbinMM, et al.SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J, 2007; 26:3169–3179.
11.
GertzM, NguyenGT, FischerF, et al.A molecular mechanism for direct sirtuin activation by resveratrol. PLoS One, 2012; 7:e49761.
12.
HubbardBP, GomesAP, DaiH, et al.Evidence for a common mechanism of SIRT1 regulation by allosteric activators. Science, 2013; 339:1216–1219.
13.
BeaudeuxJL, Nivet-AntoineV, GiralP. Resveratrol: A relevant pharmacological approach for the treatment of metabolic syndrome?. Curr Opin Clin Nutr Metab Care, 2010; 13:729–736.
14.
TimmersS, KoningsE, BiletL, et al.Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab, 2011; 14:612–622.
15.
LiangH, WardWF. PGC-1a: A key regulator of energy metabolism. Adv Physiol Educ, 2006; 30:145–151.
16.
ParkSJ, AhmadF, PhilpA, et al.Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell, 2012; 148:421–433.
17.
CroniseRJ, SinclairDA, BremerAA. The “metabolic winter” hypothesis: A cause of the current epidemics of obesity and cardiometabolic disease. Metab Syndr Relat Disord, 2014; 12:355–361.
18.
Méndez-del VillarM, González-OrtizM, Martínez-AbundisE, et al.Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord, 2014; 12:497–502.
19.
AntonSD, EmbryC, MarsiskeM, et al.Safety and metabolic outcomes of resveratrol supplementation in older adults: Results of a twelve-week, placebo-controlled pilot study. Exp Gerontol, 2014; 57C:181–187.
20.
AffusoF, MercurioV, RuvoloA, et al.A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol, 2012; 4:77–83.
